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Abstract 
Fracture healing is characterized by inflammation, cartilage formation, bone deposition, 
and remodeling. Endochondral ossification is an important part of callus formation that relies on 
the maturation of chondrocytes. Early in their maturation these cells express collagen type II 
alpha 1 chain (COL2A1) and express collagen type X alpha 1 chain (COL10A1) as they mature 
further and become hypertrophic chondrocytes. Activation of the insulin pathway is considered a 
primary factor involved in the initiation of chondrogenesis and its progression during bone 
healing. Insulin mimetics like zinc chloride (ZnCl2) have been shown to improve bone healing 
outcomes and enhance bone healing, but the mechanism by which insulin mimetics enhance 
bone healing is unclear. We hypothesized that treatment of chondrocytes with ZnCl2 would 
activate AKT within the insulin-signaling pathway and promote chondrocyte maturation and 
differentiation similar to insulin. The ATDC5 chondrogenic cell line was treated zinc chloride 
(ZnCl2) and evaluated for chondrogenesis by measuring calcium deposition, proteoglycan 
synthesis, protein expression, and gene expression at specific timepoints between 0-28 days. Our 
data demonstrates that ZnCl2 induces the insulin pathway by phosphorylation of Akt. ZnCl2 
treatment promotes chondrogenesis as seen by increased expression of chondrogenic markers 
COL2A1 and COL10A1 and calcium deposition.  
 
Keywords: chondrocyte, maturation, zinc, insulin, diabetes, fracture, regeneration, ossification 
 
 
 
 
5 
 
Introduction 
Diabetes and Bone Healing 
Diabetes mellitus is a metabolic disorder which is known to have improperly regulated 
insulin levels. Many complications associated with diabetes exist including decreased bone 
mineral density and impaired bone healing [6]. The bone impairment is projected to rise from 
171 million patients in 2000 to 366 million in 2030 [26]. Research has shown that insulin given 
locally at fracture sites accelerates fracture healing in both diabetics and non-diabetics. Insulin 
has been shown to be essential to the upregulation of chondrogenesis. Insulin insufficiency, 
hyperglycemia and oxidative stress are hallmarks of both Type 1 diabetes (T1DM) and Type 2 
diabetes (T2DM). These diabetic conditions reduce osteoblast differentiation, increase osteoclast 
activity, and alter apoptosis of chondrocytes and osteoblasts leading to impaired fracture healing 
in diabetic patients [14-21]. Clinical studies also show that diabetes delays fracture healing. In 
diabetic patients, fracture union time (normal fracture healing) may be prolonged by 87%. 
Diabetes is also associated with a relative risk of 3.4-fold for complications in osseous healing, 
including delayed reunion (prolonged fracture healing), non-union, redislocation or 
pseudoarthrosis [10]. Diabetics have slower healing rates and have higher risk of re-injury than 
non-diabetics. Local insulin treatment applied at the fracture site in both diabetics and non-
diabetics, demonstrated accelerated fracture healing [10]. Topping et al [32] reported a 54-70% 
decrease in Type X collagen in the fracture callus of diabetic rates and suggested that this might 
have a role in defective diabetic fracture healing. These studies support the theory that diabetes 
might affect fracture healing at the stage of cartilage formation [10, 32]. 
Bone regeneration is a complex, well-orchestrated physiological process of bone 
formation, which can be seen during normal fracture healing, and is involved in continuous 
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remodeling throughout adult life [1]. Fracture healing is a common form of bone regeneration 
and is characterized by inflammation, cartilage formation, cartilage bridging, bone deposition, 
and remodeling. The ability of fractures to regenerate and undergo repair may be compromised 
when an insufficient osteogenic reaction is observed in the fracture callus, and can result in 
atrophic nonunion [30]. An atrophic nonunion occurs when no callus is formed often due to 
impaired bone healing caused by vascular (e.g. impaired blood supply) or metabolic 
complications (e.g. diabetes). These atrophic nonunions are solved with bone healing 
augmentation instead of a mechanical approach which would employ the use of nails, pins, or 
other hardware. Immediately following a fracture, a hematoma forms at the site of injury 
(primary fracture healing) acting as a protective blood clot to mediate the inflammatory process 
and contribute to the removal and replacement of necrotic bone with a new bone matrix 
(secondary fracture healing) [4]. The hematoma contains fracture debris and initiates a pro-
inflammatory cascade by recruiting immune cells from the surrounding soft tissues, lymphatic 
system, and vasculature. Within a hematoma a low pH microenvironment is formed where 
inflammatory cells secrete pro-inflammatory cytokines [tumor necrosis factor α (TNF-α), 
interleukin-1β (IL-1β), and IL-6] to activate the polymorphonuclear neutrophils and M1 (or pro-
inflammatory) macrophages that are recruited to manage this acute inflammation stage [40]. 
Traumatic inflammation during fracture healing is a key sign that inflammatory cells and bone 
cells are interacting with each other through common cytokines, receptors, transcription factors, 
and signaling molecules due to communication between cells of the monocyte-macrophage-
osteoclast and MSC-osteoblast lineages [8]. Fracture healing benefits from an inflammatory 
response triggered by the immune system to stimulate secretion of signaling molecules that 
contribute to the healing process. For example, matrix metalloproteinases (MMPs) are a family 
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of zinc-dependent endopeptidases that play a crucial role in various physiological processes 
including tissue remodeling and organ development, in the regulation of inflammatory processes, 
and in diseases such as cancer [92]. Inflammatory cells immediately collaborate with the 
complement system, coagulation cascade, and neutrophils along with “emergency signals” 
triggered by cytokine/chemokine network post-trauma as the “first line of defense” initiated by 
innate immunity.  
Indirect (secondary) fracture healing has other key events that proceed hematoma 
formation, such as acute inflammation (neutrophils and macrophages are recruited, and pro-
inflammatory cytokines are produced), granulation tissue formation (angiogenesis), callus 
formation (MSCs differentiated into chondrocytes) and remodeling (formation of chondroblasts 
and osteoclasts) [5]. Inflammatory cytokines are known to have negative effects on bone, joints, 
and implanted material when prolonged or chronic expression occur [34]. Tissue regeneration 
requires a brief yet highly critical regulated secretion of inflammatory cytokines immediately 
following an acute injury. Acute inflammatory response peaks within the first 24 hours and is 
complete after 7 days [35]. Secretion of inflammatory cytokines such as tumor necrosis factor 
alpha (TNF-α), MMPs, interleukin-1 (IL-1), IL-6, IL-11, and IL-18 are known to promote 
angiogenesis and recruit other proinflammatory cytokines initially an acute injury (Figure 1). 
MMPs participate in regulating mechanisms in all of repair processes. MMPs can activate 
cytokines and chemokines by cleaving them from the cell surface or processing them to increase 
their activity, or degrade them, thereby inhibiting inflammatory signals. MMPs are involved in 
remodeling the ECM either directly by proteolytic degradation of proteins, such as collagens, or 
indirectly via their ability to affect cell behavior. Alteration of the ECM is integral to the 
resolution of wound healing but also has implication in regulation of inflammation [92]. 
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Figure 1: An overview of cytokine-mediated regulation of synovial interactions. Source McInnes & Schett (2007). 
The TNF-α concentration has been shown to peak at 24 hours and return to baseline 
within 72 hours post trauma [18]. Within that timeframe, TNF-α is expressed by macrophages, 
and act as a chemotactic agent to recruit necessary cells such as neutrophils, chondrocytes, and 
osteoblasts [36]. In vitro studies have shown that TNF-α induces osteogenic differentiation of 
MSCs [36-38]. Osteogenic differentiation is mediated by TNFR1 and TNFR2 receptors 
expressed on both osteoblasts and osteoclasts. Interleukins, IL-1 and IL-6, are expressed during 
osteogenic differentiation and is believed to be most important for fracture healing [35-38]. IL-1 
is produced by macrophages in the acute phase of inflammation and induces production of IL-6 
in osteoblasts, promotes the production of the primary cartilaginous callus, and promotes 
angiogenesis at the injured site by activating either of its two receptors, IL-1RI or IL-1RII [36-
38]. IL-6 is only produced during the acute phase and stimulates angiogenesis, vascular 
endothelial growth factor (VEGF) production, and the differentiation of osteoblasts and 
osteoclasts [39]. The anti-inflammatory state is due largely to the phenotypic modulation 
(transition from M1) of macrophages to the M2 (or alternatively activated, anti-inflammatory 
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macrophages) population in the fracture callus. These anti-inflammatory M2 macrophages 
secrete a battery of cytokines and growth factors to promote tissue repair and angiogenesis, such 
as, IL-10, PDGF, VEGF, transforming growth factor-β (TGFβ), epidermal growth factor (EGF), 
and arginase [40]. 
Figure 2: Femur fracture repair. Source Einhorn, T. A., & Gerstenfield, L.C. (2014). 
 
 
 
 
 
Angiogenesis is the formation of new blood vessels which is controlled by chemical 
signals that can stimulate both repair of damaged blood vessels and formation of new blood 
vessels [42]. Angiogenesis involves migration, growth, and differentiation of vascular 
endothelial cells aligned inside the wall of blood vessels [42]. Local and systemic factors such as 
fibroblast growth factor (FGF), transforming growth factor (TGF), bone morphogenetic protein 
(BMP) and vascular endothelial growth factor (VEGF), are active during fracture healing (Figure 
2) and are known to have direct or indirect chondrogenic, osteogenic and/or angiogenic 
functions. Endogenous VEGF is a key player in bone repair, where its temporal and spatial 
expression pattern corresponds to the one observed during long bone development [42, 43]. 
VEGF is a critical growth factor for normal angiogenesis and appropriate callus architecture and 
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is induced in osteoblasts. It regulates recruitment, survival and activity of osteoclasts, endothelial 
cells, and osteoblasts [43]. Also, VEGF has been observed to play a major role in cartilage 
maturation and resorption. Produced by hypertrophic chondrocytes, VEGF initiates the 
endochondral ossification cascade by recruiting and/or differentiating osteoclastic cells that 
resorb cartilage and by attracting osteoblasts [44, 45]. Inhibition of VEGF activity disrupts 
angiogenesis and results in non-unions (i.e. a failure to establish a bony bridging of the fracture 
gap) and delayed unions (i.e. a failure to establish a bony bridging of the fracture gap within a 
clinically reasonable period of time approximately 3-12 weeks for common fractures) [43]. 
Therefore, uninhibited growth factor activity is required to promote angiogenesis and appropriate 
bone bridging formation during fracture healing. 
Bone Formation 
There are two major modes of bone formation that involve the transformation of a 
preexisting mesenchymal tissue into bone tissue: intramembranous ossification and 
endochondral ossification [2]. Intramembranous ossification is the process of direct bone 
formation, where osteochondral progenitors differentiate directly into osteoblasts [40]. 
Intramembranous ossification also occurs in the bones of the skull where neural crest-derived 
mesenchymal cells proliferate and condense into compact nodules [2]. Osteoblasts synthesize an 
ECM containing Type I collagen. During intramembranous healing, bone spicules created from 
the osteoblasts fuse to form a trabeculated bone that is eventually fully remodeled into a cortical 
bone ultrastructure through the coordinated action of osteoblasts and osteoclasts [40]. 
Endochondral ossification is an indirect bone formation process and an important mechanism for 
callus formation that relies on the differentiation of mesenchymal stem cells (MSCs). Cartilage is 
produced via maturation of chondrocytes and is later replaced by bone.  
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All bones from the base of the skull down, except for the clavicles, are formed this way. 
The process of endochondral ossification can be divided into five stages. First, MSCs committed 
to endochondral ossification differentiate into chondroblasts. Chondroblasts secrete cartilage 
ECM, resulting in a cartilage model of the bone. Second, committed MSCs condense into 
compact nodules and differentiate into chondrocytes that proliferate rapidly to form the model 
for the bone (cartilage-specific extracellular matrix (ECM). The cartilage model continues to 
grow as chondrocytes divide and more ECM is secreted, a processc called interstitial growth. 
Appositional growth ensues when new chondroblasts in the perichondrium secrete matrix on the 
periphery of the cartilage model. Chondrocytes stop dividing when ECM is formed and become 
hypertrophic deep in the center of the cartilage model. Hypertrophic chondrocytes stop secreting 
collagen and begin to secrete an enzyme essential for mineral deposition called alkaline 
phosphatase that then cause the ECM to calcify. Calcification causes remaining chondrocytes to 
die because nutrients are difficult to transfer through a calcified matrix. Third, invasion of 
cartilage ECM model by expanding blood vessels and terminally differentiated hypertrophic 
chondrocytes die by apoptosis or undergo osteogenic transdifferentiation [2]. Osteoblasts begin 
to secrete bone matrix around any remaining calcified cartilage and begin form the primary 
ossification center. Fourth, primary ossification center spreads as osteoclasts break down newly 
formed bone. This causes formation of the medullary cavity in the diaphysis; walls of the 
diaphysis will eventually be replaced by compact bone. Last, secondary ossification centers form 
in the epiphyses following invasion by branches of the epiphyseal artery.  
Fracture repair initially begins with the formation of fracture hematoma at 6-8 hours post 
injury. Within the fracture line, blood vessels are broken causing blood to leak out and form a 
significant clot around the fracture site. Due to lack of blood circulation near fracture site, nearby 
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bone cells die, and inflammation occurs at the affected area. Fibrocartilage callus formation takes 
about 3 weeks to occur. Fibroblasts from the periosteum migrate to the fracture site and produce 
collagen fibers. Some cells differentiate into chondroblasts to produce fibrocartilage. 
Fibrocartilage callus is composed of collagen fibers and cartilage that bridges the gap in injured 
tissue. At approximately 3-4 months, bony callus forms in areas close to healthy tissue. 
Osteogenic cells differentiate into osteoblasts which begin to lay down spongy bone. Later, 
spongy bone tissue replaces fibrocartilage callus. Lastly, osteoclasts resorb dead pieces of broken 
bone and spongy bone is replaced by compact bone along the periphery of the fracture (bone 
remodeling).  
Chondrocyte Maturation 
Chondrogenic differentiation of bone marrow-derived stromal cells (BMSCs) is a 
complex interactive network between transcriptional factors, extracellular growth factors, and 
signal transduction pathways [47,48] (Figure 4). Several comparative studies have shown that the 
quality of cartilage produced by using BMSCs is substantially lower than that obtained by using 
chondrocytes [46]. Chondrocytes are cartilage-producing cells, which are derived from 
mesenchymal stem cells. The early steps of chondrogenesis, including mesenchymal 
condensation and the expression of chondrocyte-specific extracellular proteins, are crucially 
dependent upon SRY-related HMG box (Sox) family transcription factors, including Sox9, Sox5 
and Sox6 [51] (Figure 3).  
By contrast, Runt-related transcription factor-2 (RUNX2) regulates the process of 
chondrocyte hypertrophy and Runt-related transcription factor 3 (RUNX3) and Forkhead box 
A2/3 (Foxa2/3) [51]. Intrinsic chondrogenic differentiation potential of BMSCs is believed to be 
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controlled by transcription factors Sox-9 and RUNX-2, whereas TGF, like TGF-β3, as well as 
BMPs are some of the most potent inducers of BMSC chondrogenesis [46] (Figure 4). Early in  
their maturation chondrocytes express collagen Type II alpha 1 chain (COL2A1). During further  
Figure 3: Different combinations of transcription factors drive tissue-specific gene expression in immature versus 
hypertrophic chondrocytes. Source Kozhemyakin et al. (2015) 
 
 
 
 
 
 
maturation, chondrocytes express crucial gene marker such as collagen Type X alpha 1 chain 
(COL10A1). The stromal cell-derived factor-1 (SDF1)/chemokine receptor (CXCR) pathway is a 
key regulator for BMSC migration, and, in the absence of SDF1 signal, migration of these cells 
to the bone tissue has been found to be impaired [49, 50]. The process of chondrogenic 
differentiation includes six phases: mesenchymal cells (chondroprogenitors), condensed 
mesenchymal cells, chondrocytes, proliferating chondrocytes, pre-hypertrophic chondrocytes, 
and hypertrophic chondrocytes [3]. Endochondral ossification, therefore, requires 
chondrogenesis and cartilage hypertrophy as necessary precursors before ossification can 
proceed. 
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Figure 4: Possible mechanisms operative in cartilage regeneration by mesenchymal stem cells. Source Gupta et al. (2012) 
 
 
 
 
 
 
 
 
 
Activation of Insulin Pathway 
Activation of the insulin pathway is considered a primary factor involved in the initiation of 
chondrogenesis and its progression during bone healing [9]. Insulin is a polypeptide hormone 
that directly and indirectly modulates bone metabolism and skeletal regeneration among other 
physiological events. The insulin receptor (IR) belongs to a family of receptor tyrosine kinase 
(RTK) transmembrane signaling proteins, which include insulin-like growth factor-1 (IGF-1), 
and epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptors [56]. 
The IR is initially synthesized as a proreceptor and cleaved to form a 350-400kDa 
heterotetrameric receptor composed of two α-subunits and two β-subunits joined by disulphide 
bones in a β-α-α-β configuration as illustrated in Fig. 5 [57]. During receptor activation, insulin 
binds to one of two binding sites on each of the αβ monomers called, site 1 and site 2 [58]. When 
insulin first binds to site 1, a high-affinity cross-linking reaction takes place, allowing site 2 to 
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become accessible for ligand binding to activate the receptor [59, 60]. Once bound, the α-subunit 
which normally prevents autophosphorylation of the β-subunit, is inhibited causing the kinase 
Figure 5: Insulin receptor and the major signal transduction pathways used in tissue repair, biomacromolecules 
synthesis and glucose uptake. Source Hrynyk et al. (2014) 
 
 
 
 
 
 
 
 
 
activity of the β-subunit to transphosphorylate, changes conformation and increases its own 
kinase activity [61]. The signaling cascade begins with the phosphorylation of intracellular 
tyrosines located on the β-subunits of the receptor. The phosphorylated tyrosines act as docking 
sites, permitting the Shc-transforming protein (Shc) found in the cytosol to bind via their Src-
homology-2 (SH2) domains [62-64]. The signal is then transduced via a series of messenger 
molecules including Grb2 (growth factor receptor-bound protein-2), which recruits SOS (son of 
sevenless), to activate Ras [65]. After activation, Ras (member of the GTP-binding protein 
family) carries the signal via mitogen-activated protein kinase kinase kinase (Raf or MAP3K), 
mitogen-activated protein kinase (MEK) and extracellular signal-related (ERK) protein kinases. 
ERK then translocates into the nucleus where cell transcription is achieved, cell cycle activation 
occurs and DNA replicate [62]. The IR signaling pathway leads to tissue repair and wound 
healing. 
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Several studies have indicated that local insulin treatment may potentially enhance 
osseous or fracture healing in non-diabetic animals [52]. In non-diabetic mice, injection of 
insulin over the calvarium increased osteoid area, osteoblast surface area, and osteoblast number 
[54]. Dedania et al. found that local insulin delivery significantly increased the percent of 
mineralized tissue within the endosteal region of the healing defect at 4 and 6 weeks post-
osteotomy, compared with saline control animals [55]. Functional insulin receptors on rat 
osteoblasts have been identified that, when activated, stimulate osteoblast proliferation, and 
increase collagen production in vitro [53]. Insulin has been postulated to elicit an anabolic role in 
bone via insulin receptor (INSR); however, recent data has shown that the anabolic effect on 
bone is acting through an alternative receptor. Increasing data suggests that the IGF-1 receptor 
shares similar downstream events with INSR [6]. In vitro studies demonstrate that insulin can 
stimulate chondrocyte proliferation, maturation, and activity in collaboration with the local 
production of IGF-1 in the pancreas. Insulin exerts direct anabolic effects and promotes 
chondrocyte maturation in vitro. [7, 11]. Insulin administration in vivo normalizes glycemic 
control and reduces advanced glycation end products (AGE) production, thus it may also 
enhance chondrocyte survival indirectly [12, 13]. Insulin treatment on fracture healing in diabetic 
patients both in vitro and in vivo have shown to promote chondrocyte maturation leading to 
endochondral ossification [7, 11-13, 55]. Poor bone regeneration is thought to result from a 
decrease in insulin receptor activation which is needed to transmit signals to initiate tissue 
growth and repair, biomacromolecule synthesis, and glucose uptake in tissues. 
Zn2+ is the second most common trace metal found in the body, after iron, and is the 
fourth most used metal in the world, after iron, aluminum, and copper [66]. Zn2+ has been used 
since the time of the ancient Egyptians, in the form of zinc oxide (ZnO), to aide in the healing of 
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wounds and burns [67]. Zinc chloride (ZnCl2) have been shown to improve bone healing 
outcomes and accelerate bone healing in both non-diabetic and diabetic animal models [9]. 
Cellular Zn2+ levels are tightly regulated, and disturbances of Zn homeostasis have been 
associated with diabetes mellitus. Zn2+ dyshomeostasis, both systemically and in the pancreas, 
plays an intricate role in the pathology of both type 1 and type 2 DM [29]. Insulin mimetics have 
an insulin-like action both in vitro and in vivo experiments, but they do not build fat like insulin. 
It is important to discuss this pathway in detail and to highlight the effect of Zn2+ on these 
signaling events in in vitro and in vivo systems [29]. In 1980, the first report of the effectiveness 
of a zinc compound to stimulate rat adipocyte lipogenesis, mimicking action of insulin [22]. 
ZnCl2 was observed to have anti-diabetic effects in streptozotocin-induced type 1 diabetic rats 
(STZ-rats) when ZnCl2 was administered orally following the rat adipocyte experiment 
previously mentioned. [23, 24, 25].  
Insulin-like Effects of ZnCl2 
Zinc compounds are used every day in various forms like an astringent, antifungal, 
antiseptic, skin protectant, and desensitizer for dentin. Zinc is an intracellular signaling molecule 
that plays important roles in growth and development, sensory function, blood clotting, 
reproduction, and immune system [27, 28]. Zn2+ enhances tyrosine phosphorylation of multiple 
receptor protein tyrosine kinases (R-PTKs), such as insulin receptor (IR), insulin-like growth 
factor type-1 receptor (IGF-1R), and epidermal growth factor (EGFR). One of the mechanisms 
by which thisis achieved involve an increased production of reactive oxygen species (ROS), 
leading to the inhibition of protein tyrosine phosphatase (PTPase) resulting in an increased 
tyrosine phosphorylation of R-PTK. Activated R-PTKs phosphorylate multiple downstream 
targets such as insulin receptor substrates (IRSs), leading to the phosphorylation and activation 
18 
 
of the MAPK/ERK1/2 and the phosphoinositide 3-kinase (PI3-K)/protein kinase B (PKB)/Akt 
(protein kinase B) signaling pathways. ERK1/2 pathways through the activation of  
Figure 6: The potential mechanism for the insulin-like effects of Zn2+. Source Vardatsikos et al. (2013). 
 
 
 
 
 
 
 
 
transcription factors contribute to the increased nuclear activity, including gene transcription, cell 
growth, and proliferation. PI3-K/PKB/AKT pathway, through its downstream targets, such as 
Forkhead box protein O1 (FOXO1), glycogen synthase kinase 3-beta (GSK3-β) and mammalian 
target of rapamycin (mTOR) signals an increase in glucose uptake, glucose transport, glycogen 
synthesis, lipogenesis and inhibition of lipolysis and gluconeogenesis [9]. It also has potent 
antioxidant and anti-inflammatory properties [27] and has been shown to exert anti-diabetic 
effects in various experimental models and in a limited number of human studies [29]. 
Unfortunately, very little is known about the effects of zinc chloride on acceleration of fracture 
healing in diabetics. Previous studies of zinc chloride as an insulin mimetic do not provide a 
concise understanding on the mechanisms which zinc chloride uses to accelerate fracture healing 
in diabetics [22].  
19 
 
Methodology 
Cell Culture 
 ATDC5 chondrogenic cell line was cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 5% fetal bovine serum (FBS), and 1% L-glutamine, selenium, 
penicillin/streptomycin, and transferrin. ATDC5 cells were plated from a frozen stock stored in a 
-80⁰C freezer. The frozen stock vile was warmed to room temperature, and then cells were 
suspended in growth media and centrifuged for five minutes at 3000rpm. The supernatant was 
decanted, and the cells were suspended in fresh growth media and plated as needed. Cells were 
checked using an electron microscope to determine confluence, the possibility of contamination, 
and cell death. When cells reached 100% confluence, experimental treatments were conducted as 
described below. 
ZnCl2 Treatment 
 ATDC5 cells were treated with increasing doses of zinc chloride (ZnCl2) (0μM, 100μM, 
1000μM) in triplicate over specific timepoints (2, 4, 24, and 48 hours). ZnCl2-treated ATDC5 
cells were harvested in Mammalian Protein Extraction Buffer (mPer) at designated timepoints (2, 
4, 24, and 48 hours) for protein expression and RiboZol™ RNA Extraction Buffer for RNA 
expression. 
Protein Isolation 
 Adherent ZnCl2-treated ATDC5 cells were harvested with Mammalian Protein Extraction 
Buffer at specific timepoints while on ice. Growth media containing ZnCl2 treatment was 
aspirated from the plates, rinsed with cold 1X HBSS, and then aspirated again to remove fluid. 
Mammalian Protein Extraction Buffer was added to each well and the plate was placed onto a 
shaker for ten minutes to coat cells evenly while on ice. Next, a cell scraper was used remove 
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adherent cells off the plate, assist in cell lysis, and extract proteins for western blot analysis. The 
lysates for each well were stored in the -20⁰C until needed for further analysis.  
Western Blotting 
Triplicate sets of frozen protein samples in mPer buffer were thawed on ice until 
completely defrosted to prevent protein degradation. In separate microtubes, protein sample and 
2X SDS with 2-Mercaptoethanol (2-Me) were combined in a 1:1 ratio and centrifuged at 4⁰C. 
The protein mixture was heated in a dry bath at 70⁰C for ten minutes to denature the proteins. A 
4-12% NuPAGE Bis-Tris gel was run using NuPAGE MOPS Running Buffer solution. The gel 
was run for 50 minutes at 200V. Transfer apparatus and four pieces of filters paper were soaked 
in transfer buffer solution with methanol; polyvinylidene fluoride (PVDF) membrane was soaked 
for one minute in methanol only and rinsed in the NuPAGE transfer buffer solution. The transfer 
chamber was set up and sample transfer was for one hour at 30V and 100W. Following transfer, 
PVDF membranes were placed in SuperBlock solution (ThermoScientfic, Rockford, IL) for one 
hour and rocked at room temperature.  
PVDF membranes were rinsed 3X in 1X Transfer Buffer Saline with 0.1% Tween (TBS-
T) for five minutes then placed in primary antibody solution, stored +4⁰C refrigerator, and slowly 
shaken overnight. The primary antibody solution consisted of 10μM GAPDH, 10μM Akt (pan) 
or phospho-Akt (pan), 0.1% SuperBlock, and 1X TBS-T. After overnight incubation, PVDF 
membranes were rinsed 3X in 1X TBS-T for five minutes then placed in secondary antibody for 
one hour and shaken at room temperature. The secondary antibody solution consisted of 0.2μM 
anti-goat IgG-conjugated antibody, 0.2μM anti-mouse IgG-conjugated antibody, TBS-T, and 
0.1% SuperBlock. The membranes were rinsed twice in 1X TBS-T and once in 1X TBS to 
remove any remaining secondary antibody then placed in Pierce® Enhanced Chemiluminescence 
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(ECL) Western Blotting Substrate to view under UV light using the FluorChem E System 
(ProteinSimple, San Jose, CA).   
RNA Isolation 
 To prepare for RNA isolation of confluent adherent cells, all equipment was sterilized 
with 70% ethanol and confined to a specific location within the laboratory to minimize 
contamination and RNA degradation by RNases. ATDC5 cells were treated with ZnCl2 at 0μ, 
100μM, 1000μM dosages and seeded (triplicate) in 6-well plates with similar method used for 
protein isolation. Post-treatment, media was aspirated and RiboZol™ RNA Extraction Reagent 
was used to isolate RNA. ATDC5 cells were lysed by passing them through the tip of the pipette 
several times to disrupt the cell wall and release RNA. Next, lysed ATDC5 cells were transferred 
into an RNase-free microtubes and incubated at room temperature for five to ten minutes. 
RiboZol™ solution was mixed with 100μL of chloroform in a tightly secured microtubes and 
shaken vigorously for fifteen seconds to thoroughly mix the samples; this solution was incubated 
at room temperature for three minutes to allow phases to begin to separate. The samples were 
centrifuged at 12,000rpm for fifteen minutes at +4⁰C to separate the mixture into three phases: 
clear aqueous phase (RNA), white interphase (DNA), and pink phenol-chloroform phase 
(protein).  
Up to 80% of the clear aqueous phase exclusively containing RNA was carefully 
removed by pipette, placed in a fresh RNase-free microtube, and a volume of isopropanol was 
added to initialize homogenization. The samples were incubated for ten minutes at room 
temperature then centrifuged at 12,000rpm for ten minutes at +4⁰C. Supernatant was removed 
without disrupting the precipitate RNA pellet that was located at the bottom of the RNase-free 
microcentrifuge tube. The pellet was washed once with a volume of 75% ethanol that was 
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prepared with DEPC-treated RNase-free water, vortexed and centrifuged at 7,500rpm for five 
minutes at +4⁰C. The ethanol wash was carefully removed without dislodging the RNA pellet. 
The pellet was briefly air-dried for five to ten minutes at room temperature until most of the 
remaining alcohol evaporated from the microcentrifuge tube. The RNA pellet was re-dissolved 
into RNase-free water and passed through a pipette tip several times until completely dissolved. 
RNA yield and purity were determined by absorbance at A260 with a BioDrop DUO (UK, 
England) immediately after isolation process. RNA purity was determined by the ratio of 
absorbance (A260/280). Purity and concentration of RNA were confirmed via gel electrophoresis 
described below.   
RNA Gel 
RNA samples were prepped for a 1% agarose gel to verify that RNA was intact after 
isolation process. 1% agarose gel was made with 1X 3-(N-Morpholino)propanesulfonic Acid 
(MOPS) buffer. Approximately 20-25mL of agarose solution was poured into the gel 
electrophoresis apparatus then allowed to solidify for 20-40 minutes. 1X MOPS buffer was 
poured over the gel until submerged and acted as running buffer during the process. The samples 
were prepped in separate RNase-free microcentrifuge tubes and included 1μg of RNA sample, 
1X Sucrose Gel Loading Dye, and RNase-free water. All prepped samples were vortexed, 
centrifuged, and loaded into the agarose gel. The gel apparatus was set at 90V and ran for one 
hour; the RNA gel was placed on a rocker at room temperature for fifteen minutes in RNase-free 
water with GreenGlo™ Safe DNA Dye. The results of the RNA gel were visualized under UV 
light and RNA samples were viewed; RNA samples that were confirmed to be intact were used 
for reverse transcription (RT). The original RNA samples were stored at -80⁰C to prevent 
degradation. 
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Reverse Transcription (RT)/Polymerase Chain Reaction (PCR) 
 RNA samples were removed from -80⁰C storage and thawed on ice; two master mixes 
were prepared for reverse transcription (RT) and placed on ice until aliquoted into RNA samples. 
One microgram of each RNA sample was combined with 5mM dNTPs and 5mM oligo dTs and 
brought up to final volume of 16μL with RNAse free water. The RNA samples were vortexed 
and centrifuged for thirty seconds at 12,000rpm. The samples were inserted into a dry bath set at 
65⁰C for three minutes for denaturation then immediately returned to ice to reduce degradation. 
These cooled RNA samples were combined with 2μL of 10X Standard RT (Taq) Buffer, 1μL of 
RNAOUT, and 1μL of reverse transcriptase enzyme. Combined RNA reactions were vortexed, 
and centrifuged again for thirty seconds at 12,000rpm. RNA reactions were incubated in a water 
bath set at 42⁰C for one hour. After incubation, microcentrifuge tubes were placed in a dry bath 
at 95⁰C for ten minutes. Post-denaturation, RT samples were cooled at room temperature to 
promote annealing. RT samples were prepared for polymerase chain reaction (PCR) to confirm 
the presence of complimentary DNA (cDNA).  
 Each PCR reaction contained 2.5μL of cDNA, 2.5μL 10X Standard RT (Taq) Buffer, 
2.5μL 5mM dNTPs, 1.5μL 10mM primer mix, and 0.125μL Taq polymerase. The samples were 
vortexed then placed in the PCR machine and the reaction proceeded for two hours and fifteen 
minutes. DNA gel was performed to confirm RT/PCR process was successful. Table 1 is the 
thermocycling conditions used for routine PCR: 
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Table 1: Thermocycling conditions for a routine PCR. 
STEP TEMP (⁰C) TIME 
Initial Denaturation 95⁰C 30 seconds 
40 Cycles 
95⁰C 
45-68⁰C 
68⁰C 
15-30 seconds 
15-60 seconds 
1 minute/kb 
Final Extension 68⁰C 5 minutes 
Hold 4-10⁰C  
DNA Gel Electrophoresis 
 DNA gel electrophoresis was setup similarly as a RNA gel, except 1X TBE Buffer is 
used instead of 1X MOPS Buffer with a 2% agarose gel. cDNA samples were combined with 1X 
Sucrose Loading Dye and ran for one hour at 90V. The DNA gel was submerged in dH2O with 
GreenGlo™ Safe DNA Dye and rocked for fifteen minutes. DNA gel was viewed under UV 
light to determine if RNA was successfully converted into cDNA during PCR process. 
Quantitative PCR (qPCR)/Gene Expression 
Prior to qPCR, cDNA samples were diluted 1:10 to increase number of reactions that 
could be performed using a 96-well qPCR plate; 2.5μL of cDNA was added prior to distribution 
of the master mix into each well. The following solutions were thawed on ice and combined into 
a sterile microcentrifuge tube for each reaction: 12μL of 2X Absolute Blue SYBR, 1.75μL each 
of 1μM forward and reverse primer per sample, 6.5μL per sample RNase-free dH2O. The primers 
used for qPCR and gene expression were glyceraldehyde-3-phosphate dehydrogenase (GAPDH 
– housekeeping gene) for normalization, collagen type II alpha 1 chain (COL2A1), collagen type 
X alpha1 chain (COL10A1), Runx2, mTOR, ALP, and β-actin (Table 4). Total volume of the 
master mix solution was 22.5μL per well. The total volume of each well for this procedure was 
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25μL (22.5μL of master mix plus 2.5μL of cDNA). Tables 2 and 3 are the qPCR thermal cycling 
program and melt curve program: 
Table 2: qPCR Thermal Cycling Program 
 Temperature (⁰C) Time Number of cycles 
Enzyme Activation 95⁰C 15 min. 1 
Denaturation 95⁰C 15 sec. 40 
Annealing 50-60⁰C 30 sec. 40 
Extension 72⁰C 30 sec. 40 
Table 3: Melt Curve Program 
 Temperature (⁰C) Time Number of cycles 
Denaturation 95⁰C 30 sec. 1 
Starting Temp. 60⁰C 30 sec. 1 
Melting Temp. 60⁰C 10 sec. 80 
 
 
Table 4: Primer sequences for detection of COL2A1, COL10A1, β-actin, RUNX2, and mTOR were based on the coding 
sequences of the respective mRNAs. 
Oligo Name Sequence (5’ to 3’) 
gapdh_F ACCACAGTCCATGCCATCAC 
gapdh_R TCCACCACCCTGTTGCTGTA 
COL2A1_F TGGGTGTTCTATTTATTTATTGTCTTCCT 
COL2A1_R GCGTTGGACTCACACCAGTTAGT 
COL10A1_F CATGCCTGATGGCTTCATAAA 
COL10A1_R GCGTTGGACTCACACCAGTTAGT 
mTOR_F CCATCCAATCTGATGCTGGA 
mTOR_R GGTGTGGCATGTGGTTCTGT 
RUNX2_F GACGAGGCAAGAGTTTCACC 
RUNX2_R GGACCGTCCACTGTCACTTT 
ALP_F CCGATGGCACACCTGCTT  
ALP_R GGAGGCATACGCCATCACAT 
B-actin_F GACAGGATGCAGAAGGAGATTACTG 
B-actin_R CCACCGATCCACACAGAGTACTT 
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The CT values for each gene (Table 4) were normalized with GAPDH CT values. Gene 
expression was calculated using the 2-ΔΔCt method. 
Alizarin Red Staining 
Briefly, calcium containing cells were determined by Alizarin Red Staining (ARS). 
ATDC5 cells were treated under four different conditions in 12-well plates and harvested at 
timepoints: 2, 4, 7, 10, 14, 17, 21, and 28 days. The cells were treated in triplicate with 1ug/ml of 
insulin, 10μM of ZnCl2, 100μM of ZnCl2 and 100μM of vanadium. The 12-well plates were 
washed with HBSS then fixed with 10% (v/v) formaldehyde at room temperature for 15 minutes. 
Next, plates were washed twice with HBSS and 40mM Alizarin Red Staining (ARS) solution 
was pipetted into each well. The ARS stained plates were placed very carefully on a rocker at 
room temperature for 20 minutes. ARS solution was aspirated from ATDC5 cell plates then 
washed four times with HBSS while shaking for five minutes. To facilitate the removal of any 
remaining liquid, the plate was angled for two minutes and re-aspirated. For quantification of 
staining, 10% (v/v) acetic acid was added to each well and incubated at room temperature for 30 
minutes on a rocker. Using a cell scraper, the monolayer was scraped from the plate and 
transferred with 10% (v/v) acetic acid to a clean centrifuge tube. The samples were vortexed 
briefly for 30 seconds then warmed for 10 minutes in a dry bath at 85⁰C. Afterwards, the samples 
were placed on ice for five minutes then centrifuged at 13,000rpm for 15 minutes. 500μL of 
supernatant was transferred into a new centrifuge tube and 200μL of 10% (v/v) ammonium 
hydroxide was added to the supernatant. Supernatant was analyzed in aliquots of 150μL in 
triplicate in a 96-well plate and read at 405nm. 
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Glacial Blue Staining 
ATDC5 cell proteoglycans were treated under four different conditions in 12-well plates 
and harvested at timepoints: 2, 4, 7, 10, 14, 17, 21, and 28 days. The cells were treated in 
triplicate with 1ug/ml of insulin, 10μM of ZnCl2, 100μM of ZnCl2 and 100μM of vanadium. The 
12-well plates were washed twice with HBSS then fixed with 100% cold methanol for five 
minutes. Next, plates were stained with 0.1% Alcian Blue in 0.1M HCl and rocked overnight. 
The ATDC5 cell monolayers were washed three times with HBSS. Proteoglycans were extracted 
with 6M guanidine-HCl overnight. Proteoglycan concentration was read at 595nm.  
Results 
Treatment with Zinc Chloride Activates Phospho-Akt and Akt Protein Expression 
 Zinc chloride (ZnCl2) has been shown in several studies to induce chondrogenesis and 
promote chondrocyte maturation [22, 35-38]. To elucidate possible mechanisms by which ZnCl2 
induced chondrogenesis, phospho-Akt and Akt expression levels were measured at 2, 4, 24, and 
48 hours post-treatment in the ATDC5 chondrogenic cell line. Figure 8 shows that ZnCl2 
treatment upregulated phospho-Akt/Akt expression greater than the control, 0μM ZnCl2 group. 
The 1000μM ZnCl2 dose showed significantly more phospho-Akt expression compared to both 
0μM ZnCl2 and 100μM ZnCl2 dosage groups at 2, 4, and 24 hours. The 1000μM ZnCl2 dose 
increased phospho-Akt expression by 19-fold, at 4 and 24 hours post-treatment (P<0.025). 
Phospho-Akt/Akt expression treated with 0μM ZnCl2 did not activate phospho-Akt/Akt 
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expression. ATDC5 cells show a 4, 5, 15-fold increase when treated with 1000μM ZnCl2 at 2, 4, 
and 24 hours post-treatment represented by Figure 7.  
Figure 7: Phospho-Akt Protein Expression of Zinc Chloride (ZnCl2) Treated ATDC5 Cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Phospho-Akt and Akt protein expression in ZnCl2 treated ATDC5 cells. Cells were treated with denoted 
concentrations of ZnCl2. A) 4 hours; B) 48 hours. 
 
 
 
 
 
 
Figure 8 is an immunoblot of phospho-Akt and Akt expression at 4 and 48 hours post-
treatment. At 4 hours post-treatment, both phospho-Akt and Akt are expressed in all ZnCl2 
doses. The 1000μM ZnCl2 dose had significant phospho-Akt antibody expression at 4 hours 
compared to the 0μM and 100μM ZnCl2 doses. At 48 hours post-treatment there was little to no 
phospho-Akt expression in any treatment group, but Akt protein was expressed in all ZnCl2 
doses. 
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Treatment with Zinc Chloride Results in Upregulation of Chondrocyte Gene Expression Markers 
 Collagen markers were shown to have specific binding with cDNA generated from PCR. 
Figure 9 shows that ZnCl2 treated ATDC5 cells expressed specific gene markers at 2, 4, 24, and 
48 hours post-treatment when normalized with housekeeping gene, GAPDH. Collagen type II 
alpha chain is expressed in early chondrocyte maturation while collagen type X alpha chain is 
expressed by hypertrophic chondrocytes prior to apoptosis.  
Figure 9: Gene expression of ZnCl2 treated ATDC5 cells over time. 
 
The 100μM ZnCl2 dose caused a 2.9- (P=0.011), 6.1- (P<0.001), and a 1,6-fold (P<0.001) 
increase in col2a1 mRNA levels at 2, 24, and 48 hours (Figure 9A). The 1,000μM ZnCl2 dose 
also increased col2a1 mRNA levels by 3.9- (P=0.003), and 7.6-fold (P<0.001) at hours 24 and 
48 hours. At 48 hours, the 100μM ZnCl2 treated ATDC5 cultures had 0.25-fold less (P=0.009) 
collagen type X alpha chain 1 (col10a1) mRNA as compared to 0μM ZnCl2 (Figure 9B). The 
1,000μM dose of ZnCl2 significantly reduced col10a1 expression as compared to controls at 4 
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(P=0.018) and 48 (P<0.001) hours after treatment. These data suggest that the 100μM dose of 
ZnCl2 stimulates chondrocyte differentiation and that the 1,000μM dose may inhibit this process. 
Other gene markers were quantified to determine the role of ZnCl2 in the promotion of 
chondrogenesis. There were no significant differences found in Runx2 expression when 
compared between treatment groups over time (Figure 9C). The 100μM ZnCl2 dose reduced 
mTOR gene expression at 24 hours (P=0.011) as compared to the control groups but no other 
significant differences were detected. The 1000μM ZnCl2 dose significantly reduce mTOR 
expression at 48 hours (P=0.005) as compared to the control group (Figure 9D).  
Treatment with Zinc Chloride Upregulates Proteoglycan Synthesis 
Figure 10: Quantification of Proteoglycans after ZnCl2 treatment over time. 
 
 Proteoglycan synthesis was measured with Alcian Blue staining on insulin-treated and 
100μM and 1000μM ZnCl2 dose treated ATDC5 cell cultures. ZnCl2 treatment was shown to 
promote proteoglycan synthesis in ATDC5 cells and statistical differences were found after two-
way ANOVA analysis (Table 5). The data showed that proteoglycan synthesis was highest 
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between days 4 and 14 in both control and 100μM ZnCl2 treated ATDC5 cells (Figure 10, Table 
5). On day 4, controls had produced significantly more proteoglycans than either ZnCl2 treatment 
group. After two weeks (day 14), 100μM ZnCl2 treated cells had 1.5-fold more proteoglycans 
when compared to insulin-dependent media (IDM) controls. Also, the data analysis shows the 
1000μM ZnCl2 dose had a significant decrease in proteoglycan concentration between days 4 and 
14 and demonstrated high levels of cell death after treatment. 
Table 5: Two-Way Analysis of Variance: Effect on Treatment on Proteoglycan with time points. 
 Comparison of Treatment Groups at Each Time Point 
(Holm-Sidak Test P Values) 
 100uM ZnCl2 vs 
Control 
1000uM ZnCl2 vs 
Control 
100uM ZnCl2 
vs 1000uM 
ZnCl2 
2 0.989 0.983 0.904 
4 0.001 <0.001 <0.001 
7 0.838 <0.001 <0.001 
10 <0.001 <0.001 <0.001 
14 0.532 <0.001 <0.001 
21 0.204 0.402 0.062 
Treatment with Zinc Chloride Promotes Calcium Deposition 
 In comparison to proteoglycan synthesis, calcium deposition was measured during 
chondrocyte differentiation with Alizarin Red staining (ARS) on ZnCl2 treated ATDC5 cells. 
ATDC5 cells were treated every two days under three conditions: IDM (control), 10μM and 
100μM ZnCl2, and VCl2 after reaching confluence. Cells were harvested on days 2, 4, 7, 10, 14, 
17, 21, 24, and 28 days post-treatment. Based on statistical data analyzed with two-way analysis 
of variance test using time and treatment as factors, calcium deposition was shown to be similar 
for 100μM ZnCl2 dose and IDM control samples between days 2-17 (Figure 11 and 12). At days 
21, 24, and 28, the 100μM ZnCl2 dose increased calcium deposition when compared to IDM 
controls. However, there were no significant differences in calcium deposition between ATDC5 
32 
 
cells treated with 10μM ZnCl2 and IDM controls at any time point (data not shown). After day 7, 
the 1000μM ZnCl2 dose caused significant cell death in ATDC5 cells and was not evaluated in 
ARS assay. 
Figure 11: Quantification of Calcium Deposition of ZnCl2 Treatment. 
 
 
Figure 12: ARS stain assay on ZnCl2 treated ATDC5 cells. A) 2 days; B) 4 days; C) 7 days; D) 10 days; E) 14 days; F) 17 
days; G) 21 days; H) 24 days; I) 28 days Source Burgess (2017) 
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Discussion 
Zinc is an essential micronutrient required for many cellular processes, especially for the 
normal development and function of the immune system [68].  Zinc is an essential trace element 
to the function of metabolism [69]. Zinc deficiency results in a retardation of bone growth, 
development, and maintenance of bone health [70,71]. Zinc2+ acts to increase bone formation 
and mineralization, decrease bone resorption and stimulate alkaline phosphatase (ALP) activity, 
in both calvaral organ cultures and osteoblast cell cultures [72-75]. Studies have demonstrated 
that zinc has an anabolic stimulatory effect on bone formation and mineralization in vivo and 
vitro. For example, Yamaguchi and Takahashi demonstrated that administration of zinc sulfate 
for 3 days produced dose dependent increases in the contents of zinc, deoxyribonucleic acid 
(DNA), collagen and calcium, and the activity of ALP in the femoral diaphysis (cortical bone) of 
weanling rats [76]. Zinc activation of ALP in bone tissues may first cause activation of ALP and 
stimulation of collagen synthesis in osteoblasts, which are involved in bone mineralization and 
calcification [77].  
Fracture healing studies have demonstrated that insulin mimetics like zinc chloride 
(ZnCl2) can enhance bone healing and stimulate bone growth via production of TGF-β1 and IGF-
1 in bone tissues of newborn rats [78]. The mechanism by which insulin mimetic, ZnCl2, 
improves bone healing is poorly understood. The current data suggests that this insulin mimetics 
promote and enhance chondrogenesis [79], osteoblastogenesis [80], and prevents osteoblast 
proliferation [81] by acting similar to insulin. Fukumoto et al. demonstrated in vitro that IGF-1 
significantly increased chondrogenesis in dose-dependent manner when administered 
continuously throughout the culture period of periosteal explants from the medial proximal tibia 
of 2-month old rabbits. IGF-1 and TGF-β1 for the first 2 days, enhanced overall total cartilage 
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growth. Immunohistochemistry for proliferating cell nuclear antigen (PCNA) demonstrated that 
combining IGF-1 with TGF-β1 gave the strongest proliferative stimulus early during 
chondrogenesis [82]. Other data shows that in vivo insulin acts as an anabolic agent in bone 
healing and regeneration using Diabetes Mellitus Type I (T1DM) rat models because impaired 
insulin signaling in bone-forming cells results in a secondary and local insulin-like growth factor 
1 (IGF-1) deficiency [83]. Zinc chloride’s role on chondrocytes has not been thoroughly 
evaluated. We hypothesized that zinc chloride could enhance chondrocyte maturation and 
differentiation like insulin and stimulate transcriptional expression of chondrogenic markers like 
collagen type II alpha 1 chain (COL2A1) and collagen type X alpha 1 chain (COL10A1).  
Our data shows that ZnCl2 treatment can induce chondrocyte differentiation in the 
absence of insulin as measured by both proteoglycan quantification and calcium deposition. Our 
data coincides with Yamaguchi et al. who demonstrated in vitro that zinc could stimulate bone 
collagen production and increase bone calcium content in calvaria of weaning rats [73]. Our data 
also shows that ZnCl2 induces chondrocyte differentiation by transcriptional upregulation of 
chondrogenic markers of COL2A1 and COL10A1. These chondrogenic markers are expressed as 
hallmarks of chondrogenesis and endochondral ossification. ZnCl2 treatment in vivo 
demonstrated mechanical strength, including increased torque to failure, torsional rigidity, shear 
modulus, and shear stress [85]. In this study [85], fracture callus showed an increased percent 
cartilage and mineralized tissue at day 7 in ZnCl2 treated group. Cell proliferation was increased 
by local ZnCl2 in both subperiosteal and gap callus regions. VEGF and IGF-1 levels within the 
fracture callus were increased by local ZnCl2 treatment. This study demonstrates the potential 
role of local ZnCl2 as an adjunct for fracture healing [85]. This suggests that ZnCl2 treatment 
contributes to growth factor expression, which stimulates cell proliferation, cell differentiation, 
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and enhances endochondral ossification. Our data suggests that ZnCl2 upregulation of gene 
markers col2a1 and col10a1 are dose-dependent and expressed in during chondrocyte maturation 
as measured by gene expression quantification. 
Zinc chloride has been demonstrated to possibly function through similar methods as 
insulin, but the mechanism by which ZnCl2 induces chondrogenesis is still uncertain. 
Chondrogenesis has a multitude of signaling regulators and mechanisms regulate chondrocyte 
maturation and cartilage production. These include various signaling pathways, including 
fibroblast growth factor (FGF), transforming growth factor β (TGF-β)/bone morphogenetic 
proteins (BMPs), Wnt/β-cats in, Hedgehog, Notch, hypoxia, and angiogenic signaling pathways 
[86]. Our data demonstrated that ZnCl2 does not induce PI3K-Akt pathway to stimulate Runx2 
transcriptional expression within the first 48 hours of treatment. Runx2 expression was compared 
between ZnCl2 treatment groups over time, no significant differences were found. Runx2 and 
Runx3 are essential for chondrocyte maturation and regulation of limb growth, and these effects 
are carried out through RunX-induced expression of Indian hedgehog (Ihh). Ihh promotes 
chondrocyte differentiation via expansion of Sox9 expression [86]. Our data shows that ZnCl2 
treatment had no effect on Runx2 expression. This suggests Runx2 is expressed through another 
pathway. Future experiments could extrapolate other pathways in which ZnCl2 induce 
chondrogenesis. In addition, our gene expression show that ZnCl2 reduces transcriptions 
expression of mammalian Target of Rapamycin (mTOR), which is an inhibitor of Insulin 
Receptor Substrate-1 (IRS-1) [87]. The serine/threonine kinase, mTOR, is a protein kinase of the 
PI3K/Akt signaling pathway [89]. Phornphutkul et al. demonstrated that in the presence of 
rapamycin, mTOR was still expressed in late gestation fetal rats [87]. Rapamycin had a 
significant effect on early hypertrophic chondrocytes and minimal effect on chondrocyte 
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proliferation. Effect of rapamycin was measured with a phosphorylated-S6 stain [87]. 
Phosphorylated-S6 is a ribosomal protein and marker for activity of mTOR. This demonstrates 
that mTOR inhibitor, rapamycin, does not significantly affect chondrocyte proliferation. Our data 
suggests that with reduced mTOR expression, it is possible that IRS-1 can upregulate expression 
of various downstream targets of PI3K/Akt signaling pathway. Since mTOR is an Insulin 
Receptor Substrate-1 (IRS-1) inhibitor, our data suggests IRS-1 may contribute in ZnCl2 induced 
chondrogenesis. Current research suggests that FGF and insulin have a synergistic effect to 
induce chondrogenesis and work long-term collaboratively to produce fully functional cartilage 
[88]. As previously mentioned, chondrogenesis can be induced by a plethora of signaling 
pathways. Therefore, in the future we plan to investigate the mechanism by which ZnCl2 affects 
chondrogenesis utilizing next generation sequencing (NGS). 
 Overall, we demonstrate that zinc chloride (ZnCl2) can induce chondrogenesis and 
upregulate expression of downstream targets of both insulin and PI3K/Akt signaling pathway. 
We demonstrated that zinc chloride treatment on ATDC5 chondrogenic cell line promotes 
chondrocyte differentiation as seen by transcription upregulation of chondrogenic hallmarks, 
COL2A1 and COL10A1. 100μM ZnCl2 treatment group was the most abundant of proteoglycan 
content and calcium deposition when compared with IDM controls. This demonstrates that ZnCl2 
was capable of inducing chondrocyte differentiation in vitro. 
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